SWOT Analysis for UroGen Pharma Ltd

Price crossing above SMA20 today, and greater than SMA5
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
Relative Outperformance versus Industry over 1 Year
New 52 week high today
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Book Value per share Improving for last 2 years
Top Gainers
Stock with Low PE (PE < = 10)
RSI indicating price strength
Stocks near 52 Week High with Significant Volumes
Volume Shockers
High Volume, High Gain
Biggest Price Gainers from Open
Highest Recovery from 52 Week Low
Stocks Outperforming their Industry Price Change in the Quarter

PEG greater than Industry PEG
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Low Piotroski Score : Companies with weak financials
Recent Results: Declining Operating Profit Margin and Net Profits (YoY)
Declining profits every quarter for the past 2 quarters
Declining Revenue every quarter for the past 2 quarters